185 related articles for article (PubMed ID: 19258190)
1. Serum sickness, encephalitis and other complications of anti-cytokine therapy.
Vermeire S; Van Assche G; Rutgeerts P
Best Pract Res Clin Gastroenterol; 2009; 23(1):101-12. PubMed ID: 19258190
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects of biologics used for treating IBD.
Stallmach A; Hagel S; Bruns T
Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):167-82. PubMed ID: 20227030
[TBL] [Abstract][Full Text] [Related]
3. Selecting appropriate anti-TNF agents in inflammatory bowel disease.
Yun L; Hanauer S
Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):235-48. PubMed ID: 19485806
[TBL] [Abstract][Full Text] [Related]
4. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
5. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
6. State-of-the-art: Immunosuppression and biologic therapy.
Sandborn WJ
Dig Dis; 2010; 28(3):536-42. PubMed ID: 20926883
[TBL] [Abstract][Full Text] [Related]
7. Infliximab in ulcerative colitis.
Aberra FN; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
[TBL] [Abstract][Full Text] [Related]
8. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
[TBL] [Abstract][Full Text] [Related]
9. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab.
Barrie A; Plevy S
Gastroenterol Clin North Am; 2006 Dec; 35(4):883-93. PubMed ID: 17129819
[TBL] [Abstract][Full Text] [Related]
10. Medical treatment of inflammatory bowel diseases.
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2005 Jul; 21(4):443-7. PubMed ID: 15930985
[TBL] [Abstract][Full Text] [Related]
11. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
12. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
Van Assche G; Vermeire S; Rutgeerts P
Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
[TBL] [Abstract][Full Text] [Related]
13. Emerging biological treatments in inflammatory bowel diseases.
van Assche G; Vermeire S; Rutgeerts P
Minerva Gastroenterol Dietol; 2007 Sep; 53(3):249-55. PubMed ID: 17912187
[TBL] [Abstract][Full Text] [Related]
14. Assessing response and loss of response to biological therapies in IBD.
Yanai H; Hanauer SB
Am J Gastroenterol; 2011 Apr; 106(4):685-98. PubMed ID: 21427713
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.
Shah SB; Hanauer SB
Rev Gastroenterol Disord; 2008; 8(3):159-68. PubMed ID: 18957923
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
17. New cytokine therapeutics for inflammatory bowel disease.
Stokkers PC; Hommes DW
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):167-73. PubMed ID: 15588691
[TBL] [Abstract][Full Text] [Related]
18. Emerging biological treatments in inflammatory bowel diseases.
Van Assche G; Vermeire S; Rutgeerts P
Dig Dis; 2006; 24(1-2):131-6. PubMed ID: 16699271
[TBL] [Abstract][Full Text] [Related]
19. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
20. Risk of infections associated with biological treatment in inflammatory bowel disease.
Andersen NN; Jess T
World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
